vaccine

Gene set enrichment analysis of HIV-envelope stimulated PBMCs revealed that the RV144 vaccine induced genes associated with antigen presentation and antiviral functions. Specifically, Fourati et al., linked IFN-γ responses with…

Understanding immune responses in individuals who have HIV superinfections* could be the key to understanding how the immune system responds to sequential exposure...

The innate signatures for 4 HIV recombinant vaccine vectors (MRKAd5/HIV, ALVAC ,MVA and Vesicular Stomatitis Virus (VSV) and their respective adjuvants have been evaluated or are under...

The lymph nodes has shown to be one compartment with highest rates of HIV replication and yet has a restrictive trafficking of cytotoxic CD8 T-cells into the tissues (Michael Betts).…

7th August 2018 Bekker and colleagues conducted the HVTN100 phase 1/2a clinical trial which aimed at determining the safety and immunogenicity of the Subtype C ALVAC-HIV and bivalent subtype C…

10th July 2018 One of the major challenges of developing a vaccine against HIV, is the extensive HIV strain diversity. One approach being ...

3rd July 2018 A collaborative research project between researchers in South Africa and US, examined the antibody repertoire in HIV ...

22nd June 2018 One of the goals in developing an effective, global HIV vaccine is to elicit potent antibodies, capable of neutralizing the majority of circulating HIV strains. These antibodies…

28th May 2018 Vaccari et al, hypothesized that changing vaccine type and/or vector may improve efficacy of the ALVAC-SIV+ gp120 alum vaccine. They tested a DNA-SIV...

28th March 2018 The RV144 or Thai Trial conducted in Thailand, is the only HIV vaccine trial to date that has demonstrated modest ...

19th January, 2018 One goal in HIV vaccine research is the development of an antibody-based vaccine to prevent HIV acquisition. Eliciting antibodies...

22nd September, 2017One avenue that is being explored in a HIV vaccine is eliciting neutralising antibody responses. However, the diversity of the virus has made this challenging. Researchers from the…

24th July, 2017One of the challenges with HIV antibody-based candidate immunogens is that they have failed to elicit broadly neutralizing antibody (bnAb) responses. HIV is a...

10th July, 2017The development of an effective HIV vaccine is highly dependent on using the right immunogen capable of eliciting a strong immune responses. The use of recombinant...

30th June, 2017Antiretroviral therapies (ART) are highly effective at supressing HIV in HIV positive individuals and yet, thousands of people are infected with HIV every day...

5th June 2017 One of the challenges with eliciting broadly neutralizing antibodies (bnAbs) which target HIV is that they have unusual characteristics...

More than 30 years after the discovery that HIV is the cause of AIDS, there is still no vaccine for this virus. One of the challenges...

27th March, 2017 Broadly neutralizing antibodies are of great importance to the HIV vaccine field.

13th March, 2017 Designing a HIV immunogen capable of eliciting broad antibody responses has been a challenge in the field. The highest efficacy in an HIV vaccine trial was 31%…

19th December, 2016The development of a successful HIV vaccine may require the induction of broadly neutralizing antibodies. Understanding how HIV...

2nd December, 2016In this age when there is readily available pre- and post-exposure prophylaxis and effective anti-retroviral therapy which enables HIV-positive individuals to have higher life expectancy...

2nd November, 2016Although most HIV vaccine research focuses on eliciting antibody response, T cells should not be forgotten. An HIV vaccine eliciting T cells to conserved...

17th October, 2016Curing HIV has proven difficult with only two reported cases of a functional cure. To add to this, there is still no effective HIV vaccine that has been…

September 9th, 2016 Broadly neutralising antibodies (bnAbs) against HIV have been one of the the main focuses in the design an effective HIV vaccine. However, since the Thai RV144 HIV…

A vaccine that can elicit neutralizing antibodies to HIV, and thus lead to protection from infection, is the holy grail of..

The 1st December 2015 is World AIDS day and another year of progress towards ending the epidemic. There are now 15 million people on life-saving antiretroviral drug treatments

Nov 30th, 2015 It is desirable to strive towards an HIV vaccine that elicits mucosal protective immunity to prevent infection of immune cells

A novel vaccine that can be administered orally has been shown...

Initial immune responses to most vaccines are impaired in people with HIV. However, little is known about the persistence of vaccine-induced antibodies over the long-term. A team of French writers…